Second-line therapy for severe pediatric ulcerative colitis

被引：0
|
作者：
Susan R. Orenstein
机构：
来源：
Current Gastroenterology Reports | 2009年 / 11卷 / 3期
关键词：
Ulcerative Colitis; Ulcerative Colitis Patient; Toxic Megacolon; Intravenous Steroid; Steroid Dependency;
D O I：
10.1007/s11894-009-0026-2
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：167 / 169
页数：2
相关论文
共 50 条
  • [21] FIRST-LINE AND SECOND-LINE BIOLOGIC AGENTS AND SMALL MOLECULES IN THE MANAGEMENT OF MODERATE-SEVERE ULCERATIVE COLITIS: A GRADE-BASED APPROACH
    Singh, Siddharth
    Fumery, Mathurin
    Dulai, Parambir
    Murad, Mohammad
    Sandborn, William J.
    GASTROENTEROLOGY, 2017, 152 (05) : S592 - S593
  • [22] Infliximab therapy for severe ulcerative colitis
    Fahrtash, Farzan
    Gibbs, Oliver
    Liddle, Christopher
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 102 - 102
  • [23] Infliximab therapy for pediatric ulcerative colitis
    Oliva-Hemker, M
    Roper, S
    Cuffari, C
    Leibowitz, A
    GASTROENTEROLOGY, 2002, 122 (04) : A616 - A616
  • [24] Severe Acute Ulcerative Colitis: The Pediatric Perspective
    Turner, Dan
    DIGESTIVE DISEASES, 2009, 27 (03) : 322 - 326
  • [25] Intravenous corticosteroid therapy for severe pediatric ulcerative colitis: Predictors of response and outcome
    Turner, Dan
    Walsh, Catharine M.
    Chow, Christy
    Walters, Thomas
    Mclernon, Robin A.
    Griffiths, Anne M.
    GASTROENTEROLOGY, 2007, 132 (04) : A514 - A514
  • [26] IMMUNOMODULATOR CO-THERAPY IMPROVES MEDICATION PERSISTENCE OF FIRST-LINE ANTI-TUMOR NECROSIS FACTOR AGENTS AND FIRST-LINE VEDOLIZUMAB, BUT NOT SECOND-LINE THERAPY, IN MODERATE-TO-SEVERE ULCERATIVE COLITIS
    Pudipeddi, Aviv
    Ko, Yanna
    Paramsothy, Sudarshan
    Leong, Rupert W.
    GASTROENTEROLOGY, 2021, 160 (06) : S343 - S344
  • [27] Factors predicting risk of colectomy in patients receiving first line steroid and second line biologic salvage therapy for Acute Severe Ulcerative Colitis
    Skinezes, Y.
    Meir, Z. Y.
    Abitbol, C. M.
    Levartovsky, A.
    Klang, E.
    Kopylov, U.
    Ben-Horin, S.
    Ungar, B.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I382 - I382
  • [28] Effect of meropenem with or without immunoglobulin as second-line therapy for pediatric febrile neutropenia
    Kobayashi, Ryoji
    Suzuki, Daisuke
    Sano, Hirozumi
    Kishimoto, Kenji
    Yasuda, Kazue
    Kobayashi, Kunihiko
    PEDIATRICS INTERNATIONAL, 2014, 56 (04) : 526 - 529
  • [29] Factors predicting risk of colectomy in patients receiving first line steroid and second line biologic salvage therapy for Acute Severe Ulcerative Colitis
    Skinezes, Y.
    Meir, Z. Y.
    Abitbol, C. M.
    Levartovsky, A.
    Klang, E.
    Kopylov, U.
    Ben-Horin, S.
    Ungar, B.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I382 - I382
  • [30] Effective Alternative for Second-Line Therapy
    不详
    OBESITY FACTS, 2009, 2 (01) : 57 - 57
12345